Navigation Links
Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
Date:10/18/2007

DALLAS, Oct. 18 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that its collaborators will be presenting clinical and preclinical data on its lead anticancer compound, ProLindac(TM), at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" taking place October 22-26, 2007 at the Moscone Convention Center West in San Francisco, CA.

An update on Access' ongoing ProLindac Phase 2 clinical study will be presented during Poster Session A, "Clinical Trials" in Abstract #A145 entitled "AP5346, a pH-dependent polymer-vectorized DACH, is safe at pharmacodynamically active doses: Results from an ongoing phase II trial in borderline potentially platinum-sensitive ovarian cancer (OC) patients" on Tuesday, October 23, 2007 from 12:30 p.m. PDT.

New ProLindac preclinical data will appear in two posters presented during Poster Session C, Novel Drug Delivery Systems, on Thursday, October 25, 2007 from 12:30 p.m. PDT:

Abstract #C105 : "Molecular and cellular effects of AP5346, a novel DACH- platinum linked polymer-compound, compared to oxaliplatin and cisplatin in a panel of human cancer cell lines."

Abstract #C110: "Antiproliferative activity of AP5346, a novel DACH- platinum compound, alone and in combination with other cytotoxics, in human colon and ovarian cancer cells."

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...wswire-FirstCall/ -- , - Not for UK Journal... Products for Human Use (CHMP) today,announced it...el(R),(etanercept) as a treatment for children ag...laque psoriasis. If approved by the European,Comm...Enbrel will become the,first biologic treatment i...
(Date:11/20/2008)...Nov. 20 GlaxoSmithKline (...es Food and Drug Administration (FDA) granted acce... the treatment of thrombocytopenia in patients wit...pura (ITP) who have had an insufficient response t... The approval is a significant milestone for PROMA...
(Date:11/20/2008)...FirstCall/ -- Duska Therapeutics,Inc., (OTC Bull...mitted its,pivotal Phase 3 ATPace clinical trial ...ssment (SPA) procedure with the U.S. Food and Drug...ng an agreement with the FDA, Duska intends to ini...o-controlled and randomized Phase 3,clinical tria...
(Date:11/19/2008)... Posit Science Corporation,researcher, Dan Tinker...ce,Annual Conference in Washington, DC this week ...by Boomers. The computerized brain plasticity-bas...ises that target auditory and,language systems. ...mprovements in cognition by improving speed and ac...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Location location location important for genes too 4646 1Location location location important for genes too 4646 2VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 1VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 2Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 1Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 1Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 3Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 4
...2007 /PRNewswire/ -- Addex Pharmaceuticals,announc...proof of,concept trial with its lead compound ADX1... its primary objective, the absence of,pain at 2 h...and,also showed trends towards improvement in pain...ther time points. ADX10059 has,already recently de...
...WIRE)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasda...ase III,AIR-CF2 study evaluating aztreonam lysine ...stic fibrosis (CF) who have,pulmonary Pseudomonas ... treatment course of aztreonam lysine significantl...nous (IV) antibiotics versus,placebo. All patients...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
(Date:11/21/2008)... Nov. 21 New research a...a smokeless, spitless tobacco product aimed at you... found that RJ Reynolds, Camel Snus - touted as a ...tains surprisingly high levels of nicotine. , ...other snuff products," said Bruce Adkins of the st...
(Date:11/21/2008)...J., Nov. 21 Today, presc...ervention in treating 88 percent of patients suffe...ans treated for a chronic condition account for 96...percent of all medical costs. A proprietary new p...Health Solutions, Inc. (NYSE: MHS ) significantl...
(Date:11/21/2008)...RNewswire/ -- In a statewide survey, 33 physicians...or Surgery at Presbyterian Hospital of Dallas were...ting of " Super Doctors ." , , Each year, t...fessional Media, Inc. to survey more than 38,000 m...ask, "If you needed medical care, which doctor wou...
(Date:11/21/2008)...bacco use is more prevalent and smoking cessation ...yperactivity Disorder (A.D.H.D.) In a study of sm...ptoms, those who exhibited elevated hyperactivity ...ed lower quit rates after 8 weeks than those with ...D.H.D. symptoms. The study, now available online ...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...l technology to rapidly screen thousands of drugs ... health threats// in the United States — diabetes ...ular biology and pharmacology at Washington Univer...nd Thomas Baranski, M.D., Ph.D., professor of medi...
...al synapses, microanatomical structures similar to...the Board of Governors' Gene Therapeutics Research...firmed the existence of anatomical structures that... a T cell and its target, an antigen-presenting br...
...interest of researchers from Auckland University, ...ma in humans, after the trials// on rats proved su...rd to having a few volunteers on board to investig...served an increase in allergies like asthma with c...
...ct surgery is higher in patients who have taken al... prostate.// According to the 3 medical associati...erican Society of Cataract and Refractive Surgery ..., mentioning the use of drugs like Flomax (tamsulo...
Other Medicine News:Health News:New Company Will Seek Drugs Against Diabetes and Cancer 2Health News:New Company Will Seek Drugs Against Diabetes and Cancer 3Health News:Alpha-blockers call for modification in cataract surgery 2Health News:Alpha-blockers call for modification in cataract surgery 3
...ons stand alone. It can also be installed as part ...a management system which can be used in ophthalmi...us, retinal surgeries are supported through the mo...per charts. They are supported on tablet PC techno...
...n a powerful, easy-to-use medical practice design ...and business requirements and situations of an oph...rovide patient care assistance as well as ensure d... for Eye's simple "point and click" or touch scree...
...ion to assist you in managing your optometric prac...hrough the creative use of technology. No more nee...waiting to see the doctor. No more wasting time se... handwriting on all paperwork. Give your administr...
...c Medical Office (EMO) for the Optometry specialis...n addition to retrieving and storing your charts e...e patient office flow including documentation of p... billing information. ChartLogic also gives you da...
Medicine Products: